Abbott Laboratories is expected to report Q1 2026 revenue of $11.02 billion and earnings of $1.14 per share, with shares currently trading around $100.69 against a consensus price target of $134.20. Investors are primarily focused on the integration and early performance of the recently closed $23 billion acquisition of Exact Sciences, which is expected to significantly boost cancer diagnostic revenues.
Sustained momentum in the Diabetes Care segment, specifically FreeStyle Libre CGM sales, remains a critical organic growth driver as the company expands its wearable sensor technology. Analysts are also watching for a recovery in the Nutrition business following prior-year pricing adjustments and the management's ability to maintain high single-digit organic growth guidance despite broader sector volatility.